OCULAR THERAPEUTIX, INC Restructuring Charges
OCULAR THERAPEUTIX, INC (OCUL) reported Restructuring Charges of $1.60 million for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-11-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2024-11-14
- OCULAR THERAPEUTIX, INC restructuring charges for the quarter ending 2024-06-30 was $1.60M.
- OCULAR THERAPEUTIX, INC restructuring charges for the quarter ending 2017-12-31 was $417.00K.
- OCULAR THERAPEUTIX, INC restructuring charges for the quarter ending 2017-09-30 was $2.09M.
- OCULAR THERAPEUTIX, INC restructuring charges for fiscal 2019 was $2.51M.
- OCULAR THERAPEUTIX, INC restructuring charges for fiscal 2017 was $2.51M.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2024-06-30 | $1.60M 10-Q · filed 2024-11-14 | |||
| 2019-12-31 | $2.51M 10-K · filed 2020-03-12 | |||
| 2017-12-31 | $417.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $2.51M derived: sum of 2 quarters · filed 2019-03-07 | $2.51M 10-K · filed 2019-03-07 | |
| 2017-09-30 | $2.09M 10-Q · filed 2017-11-07 | $2.09M 10-Q · filed 2017-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |